|Title:||Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)||Authors:||PEI-LUNG CHEN||Issue Date:||2018||Publisher:||Elsevier Ireland Ltd||Journal Volume:||277||Start page/Pages:||234-255||Source:||Atherosclerosis||Abstract:||
Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ?2/3 countries. Lipoprotein-apheresis is offered in ?60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. ? 2018 Elsevier B.V.
|ISSN:||0021-9150||DOI:||10.1016/j.atherosclerosis.2018.08.051||metadata.dc.subject.other:||Article; awareness; familial hypercholesterolemia; genetic screening; government; health program; human; knowledge; lipoprotein apheresis; prevalence; priority journal; public health problem; adverse event; apheresis; blood; cooperation; familial hypercholesterolemia; genetic predisposition; global health; health care delivery; health care disparity; health care survey; international cooperation; phenotype; predictive value; risk factor; treatment outcome; biological marker; hypocholesterolemic agent; low density lipoprotein cholesterol; Anticholesteremic Agents; Biomarkers; Blood Component Removal; Cholesterol, LDL; Cooperative Behavior; Genetic Predisposition to Disease; Global Health; Health Care Surveys; Health Services Accessibility; Healthcare Disparities; Humans; Hyperlipoproteinemia Type II; International Cooperation; Phenotype; Predictive Value of Tests; Prevalence; Risk Factors; Treatment Outcome
|Appears in Collections:||基因體暨蛋白體醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.